Vidac Pharma Ltd receives “Seal of Excellence” from the European Commission Horizon Program
Vidac Pharma Seal of Excellence 2023
Vidac Pharma Holding Plc is proud to announce that it received high appreciation for its Clinical Proposal for treatment of Non-Melanoma Skin Cancer (NMSC)
Vidac pharma Holding Plc (XSTU:SYM: T9G; ISIN: GB00BM9XQ619; WKN: A3DTUQ)
Vidac Pharma Holding Plc is proud to announce that Vidac Pharma Ltd, its operational arm received high appreciation for its Clinical Proposal for treatment of Non-Melanoma Skin Cancer (NMSC) and received the “Seal of Excellence” from the “Horizon Europe EIC Accelerator Program following evaluation by an international panel of independent experts and was recognized as a high-quality project proposal in a highly competitive evaluation process”. We are happy to share enclosed the Official announcement received. Dr. Max Herzberg, Chairman of the Board commented that "receiving such a distinction opens many opportunities to the Company in terms of cooperation and funding as well as a follow up specific guidance of its management group offered by EIC selected experts".
Disclaimer
The following information does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only.
Vidac Pharma Holding PLC
Dr. Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381
+972 (0)779300647
Max Herzberg
Vidac pharma Holding Plc
+972 54-425-7381
email us here
Visit us on social media:
LinkedIn
Distribution channels: Banking, Finance & Investment Industry, Chemical Industry, Companies, Healthcare & Pharmaceuticals Industry, Science
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Submit your press release